Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · BioLife Solutions (BLFS)

BioLife Solutions Q2 revenue rises 29% to $25.4 million; raises 2025 revenue guidance

Mixed Impact 4 of 5 earnings Written later

BioLife Solutions reported unaudited second-quarter 2025 revenue of $25.4 million, up 29% from a year earlier, and raised its full-year 2025 revenue guidance to $100.0 million to $103.0 million. The GAAP net loss widened to $15.8 million, which includes a non-cash $15.5 million in-process R&D expense tied to the April 2025 PanTHERA acquisition.

Key points

  • Q2 2025 total revenue was $25.4 million, up from $19.7 million in Q2 2024.
  • GAAP net loss from continuing operations was $15.8 million, versus $5.6 million a year earlier, including a $15.5 million non-cash IPR&D expense.
  • Full-year 2025 revenue guidance was raised to $100.0 million to $103.0 million from $95.5 million to $99.0 million.
  • Adjusted EBITDA was $6.1 million, or 24% of revenue, compared with $3.9 million, or 20% of revenue, in Q2 2024.

The filing

CompanyBioLife Solutions (BLFS)
Form8-K, current report
Filed with the SECAug 7, 2025, 4:10 PM ET
Accession number0000834365-25-000014

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 2:07 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 07, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.